Cargando…
Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment
Anti-vascular endothelial growth factor treatment for macular edema secondary to branch retinal vein occlusion generally provides good visual acuity (VA) improvement but may require repeated injections for years. To reduce the number of patients who suffer from avoidable VA loss caused by treatment...
Autores principales: | Murata, Toshinori, Kondo, Mineo, Inoue, Makoto, Nakao, Shintaro, Osaka, Rie, Shiragami, Chieko, Sogawa, Kenji, Mochizuki, Akikazu, Shiraga, Rumiko, Kaneko, Takeumi, Chandrasekhar, Chikatapu, Tsujikawa, Akitaka, Kamei, Motohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090796/ https://www.ncbi.nlm.nih.gov/pubmed/35538139 http://dx.doi.org/10.1038/s41598-022-11113-y |
Ejemplares similares
-
The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients
por: Murata, Toshinori, et al.
Publicado: (2021) -
Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients
por: Murata, Toshinori, et al.
Publicado: (2021) -
Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration
por: Shiragami, Chieko, et al.
Publicado: (2017) -
CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS
por: Osaka, Rie, et al.
Publicado: (2018) -
MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: Takasago, Yukari, et al.
Publicado: (2019)